Welcome to our dedicated page for Sionna Therapeutics SEC filings (Ticker: SION), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sionna Therapeutics, Inc. (Nasdaq: SION) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Sionna describes itself as a clinical-stage biopharmaceutical company focused on developing CFTR-targeted therapies for cystic fibrosis, and its filings offer detail on this business and its financial position.
Among the key documents available are current reports on Form 8-K, where Sionna furnishes press releases announcing quarterly financial results and business highlights. For example, the company has used Form 8-K to present information on research and development expenses, general and administrative expenses, net loss, cash and cash equivalents, and progress across its clinical pipeline of NBD1 stabilizers and complementary CFTR modulators.
In addition to 8-Ks, investors typically look to annual reports on Form 10-K and quarterly reports on Form 10-Q for broader discussions of risk factors, research and development activities, and the company’s focus on cystic fibrosis therapies. These filings can also describe Sionna’s status as an emerging growth company, its operating segment dedicated to CF drug development, and other structural aspects of the business.
Stock Titan enhances access to SION filings by pairing real-time updates from the EDGAR system with AI-powered summaries that explain the significance of each document in clear language. Users can quickly identify items related to clinical trial progress, financial condition, and other material events, and can review insider and management-related disclosures where applicable. This page serves as a central location for reviewing Sionna’s regulatory history and understanding how its CF-focused strategy is reflected in formal SEC documents.
Viking Global Investors LP amended its Schedule 13G/A to remove David C. Ott as a reporting person effective March 31, 2026. The filing restates beneficial ownership by related Viking entities and individuals: 3,195,181 shares (representing 7.1% of the class) held through affiliated funds and GPs.
The amendment details that 2,039,801 shares are directly owned by Viking Global Opportunities Sub‑entities and 1,155,380 shares by Viking Global Opportunities Drawdown entities, with shared voting and dispositive power across the reported affiliates and two executive committee members.
Sionna Therapeutics Inc ownership update: Qatar Investment Authority, through wholly owned Q Healthcare Holding LLC, reports beneficial ownership of 2,020,258 shares of Common Stock, representing 4.5% of the class. The Schedule 13G/A amendment identifies sole voting and dispositive power over these shares.
Sionna Therapeutics reports first-quarter 2026 results showing a net loss of $26.8 million, wider than $16.5 million a year earlier, as it invests heavily in cystic fibrosis drug development. Research and development expenses rose to $19.0 million and general and administrative costs to $10.6 million, both driven mainly by higher headcount and stock-based compensation.
The company ended March 31, 2026 with $289.9 million in cash, cash equivalents and marketable securities and expects this to fund operations into 2028. Sionna is running a Phase 2a trial of NBD1 stabilizer SION-719 as an add-on to Trikafta and a Phase 1 dual-combination trial of SION-451 with two complementary CFTR modulators, with topline data from both studies anticipated in the summer of 2026. It also established a $250.0 million at-the-market equity program but has not yet issued shares under it.
Sionna Therapeutics, Inc. reported first quarter 2026 results and a business update focused on its cystic fibrosis pipeline. The company completed enrollment in its PreciSION CF Phase 2a proof‑of‑concept trial of NBD1 stabilizer SION-719 as an add-on to standard of care, with topline data expected in summer 2026. An ongoing Phase 1 trial of NBD1 stabilizer SION-451 in dual combinations with SION-2222 and SION-109 is also on track for topline data in the summer.
Research and development expenses were $19.0 million and general and administrative expenses were $10.6 million for the quarter, leading to a net loss of $26.8 million, or $0.60 per share. Sionna ended March 31, 2026 with $289.9 million in cash, cash equivalents and marketable securities, which it expects to fund operations into 2028.
Sionna Therapeutics, Inc. director reporting person Peter A. Thompson reported indirect open-market sales of company common stock by an affiliated OrbiMed investment entity. Over three transactions on May 7, 8, and 11, 2026, the entity sold a total of 292,952 shares at prices between $44.58 and $46.22 per share under a pre-arranged Rule 10b5-1 trading plan. The shares are held of record by OrbiMed Private Investments VIII, LP, for which OrbiMed Capital GP VIII LLC and OrbiMed Advisors LLC may be deemed to share voting and investment power. Following these sales, the OrbiMed entity associated with the reporting person continues to hold 2,671,822 shares of Sionna Therapeutics common stock indirectly, with beneficial ownership disclaimed except to the extent of any pecuniary interest.
OrbiMed-affiliated funds reported open-market sales of Sionna Therapeutics, Inc. common stock. OrbiMed-related entity OrbiMed Private Investments VIII, LP sold 48,546 shares on May 7, 2026 at $44.61 per share, 59,767 shares on May 8, 2026 at $44.58 per share, and 184,639 shares on May 11, 2026 at $46.22 per share.
All sales were executed as open-market transactions pursuant to a Rule 10b5-1 trading plan. Following these transactions, the OrbiMed-affiliated holder reported owning 2,671,822 shares of Sionna Therapeutics common stock indirectly.
Sionna Therapeutics files its Annual Report describing a clinical-stage CF franchise focused on NBD1 stabilizers and complementary modulators. The company reports lead programs SION-719 (Phase 2a PreciSION CF add-on to Trikafta) and SION-451 (Phase 1 dual-combination evaluation), with topline Phase 1 safety and PK data announced in June 2025 and Phase 2a enrollment of ~16 participants ongoing.
The report details preclinical validation using a CFHBE translational model linking in vitro chloride transport to sweat chloride and FEV improvements, patent families and license agreements with Sanofi and AbbVie, key development milestones, and material risks including continued operating losses and financing needs.
Sionna Therapeutics, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 17, 2026 at 12:00 p.m. Eastern Time. Stockholders will elect four class II directors to serve until 2029 and ratify Deloitte & Touche LLP as independent auditor for 2026.
Stockholders of record at the close of business on April 21, 2026, when 45,142,330 common shares were outstanding and entitled to vote, may participate. The company is using the SEC “Notice and Access” process, providing proxy materials online and offering Internet, telephone, mail, and in‑meeting voting options.
Sionna Therapeutics director-affiliated entity sells SION shares under 10b5-1 plan
Entities associated with director Peter A. Thompson reported open-market sales of a total of 55,345 shares of Sionna Therapeutics common stock at prices around $44.5 per share over two days. The transactions were executed pursuant to a Rule 10b5-1 trading plan, indicating they were pre-arranged.
The shares are held of record by OrbiMed Private Investments VIII, LP, with OrbiMed Capital GP VIII LLC and OrbiMed Advisors LLC potentially deemed to share voting and investment power. After these sales, OrbiMed’s reported indirect holdings stand at 2,964,774 shares of Sionna Therapeutics common stock, and all reporting parties expressly disclaim beneficial ownership beyond any pecuniary interest.
OrbiMed-affiliated funds reported open-market sales of Sionna Therapeutics, Inc. common stock. OrbiMed-related entities sold 52,397 shares on April 17 at $44.68 per share and 2,948 shares on April 18 at $44.52 per share, under a pre-arranged Rule 10b5-1 trading plan. After these indirect transactions through OrbiMed Private Investments VIII, LP, the reporting entities continued to hold 2,964,774 shares of Sionna Therapeutics common stock.